A share price of Corcept Therapeutics Inc [CORT] is currently trading at $76.81, up 6.50%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CORT shares have lost -13.14% over the last week, with a monthly amount glided 7.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
Corcept Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $42.01 and $117.33. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $76.81 at the most recent close of the market. An investor can expect a potential return of 82.27% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Trailing Twelve Months sales for Corcept Therapeutics Inc [NASDAQ:CORT] were 716.08M which represents 18.70% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.2 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Corcept Therapeutics Inc [NASDAQ:CORT] is 3.06. As well, the Quick Ratio is 2.98, while the Cash Ratio is 0.71. Considering the valuation of this stock, the price to sales ratio is 11.30, the price to book ratio is 12.72 and price to earnings (TTM) ratio is 68.35.
Transactions by insiders
Recent insider trading involved Swisher Daniel N JR, Director, that happened on Oct 10 ’25 when 2200.0 shares were sold. Director, Swisher Daniel N JR completed a deal on Oct 10 ’25 to buy 2200.0 shares. Meanwhile, Chief Development Officer Guyer William sold 20000.0 shares on Oct 07 ’25.
